FDA Posts Investigator In Singapore, But Trims Foreign Office List
This article was originally published in The Tan Sheet
FDA's Office of International Programs consolidates its China offices to "strategically focus its resources." FDA shifts away from primarily a domestic focus to global as drug criminal organizations spread globally
You may also be interested in...
FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.
Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in interview with “The Pink Sheet.”
President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.